Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
63 hedge funds and large institutions have $55.1M invested in Kaleido Biosciences, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 23 reducing their positions, and 8 closing their positions.
34,200% more call options, than puts
Call options by funds: $343K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 66 → 63 (-3)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
32% less capital invested
Capital invested by funds: $80.8M → $55.1M (-$25.7M)
52% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$84.8K |
| 2 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$69.3K |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$21.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.04K |
| 5 |
State Street
Boston,
Massachusetts
|
+$8.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$298K |
| 2 |
Millennium Management
New York
|
-$86.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$81.2K |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$55.9K |
| 5 |
E
Ergoteles
New York
|
-$47K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| $1K | -$19.2K | -10,750 | -96% |
|
52
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
|
LWANC
53
Laurel Wealth Advisors (North Carolina)
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
54
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$81.2K | -45,490 | Closed |
|
|
E
55
Ergoteles
New York
| – | -$47K | -19,600 | Closed |
|
56
D.E. Shaw & Co
New York
| – | -$45K | -18,827 | Closed |
|
57
Goldman Sachs
New York
| – | -$43K | -18,060 | Closed |
|
|
ACM
58
Aquatic Capital Management
Chicago,
Illinois
| – | -$7K | -3,100 | Closed |
|
|
SOW
59
State of Wyoming
Cheyenne,
Wyoming
| – | -$5K | -2,236 | Closed |
|
60
Koshinski Asset Management
Decatur,
Illinois
| – | -$1.43K | -600 | Closed |
|
|
CAL
61
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$235 | +132 | New |
|
|
PFS
62
Prospera Financial Services
Dallas,
Texas
| – | +$357 | +200 | New |
|
|
GRP
63
Global Retirement Partners
San Rafael,
California
| – | +$473 | +265 | New |
|
KLDO Hedge Fund Activity: Q1 2022 in Review
63 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q1 2022, worth a combined $55.1M — down 32% from $80.8M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of KLDO and 6 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 11 added.
The largest buyer was Renaissance Technologies, adding an estimated $84.8K. The largest seller was Vanguard Group, cutting an estimated $298K.
- 63 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q1 2022, down from 66 in Q4 2021.
- Funds reported $55.1M of Kaleido Biosciences, Inc. Common Stock stock for Q1 2022, down 32% quarter-over-quarter.
- 6 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q1 2022 and 8 closed out, a net change of -2 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $84.8K added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q1 2022 was Vanguard Group, an estimated $298K sold.
Based on aggregated 13F filings for Q1 2022.